The single arm phase II CALYPSO study evaluated the efficacy of MET inhibitor savolitinib combined with PD-L1 inhibitor durvalumab in…
Cristina Suárez
Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based…
The phase 2, international, multicenter SUNNIFORECAST study, directed by Lothar Bergmann of the Medical Clinic II, University Hospital Frankfurt in…
The phase 3 open-label, randomized NIAGARA trial was designed to evaluate the benefits of adding perioperative immunotherapy durvalumab to standard…
Results of the phase III LITESPARK-005 clinical trial show that treatment with belzutifan versus everolimus significantly improves progression-free survival in…
Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
Led by Toni K. Choueiri at the Dana Farber Cancer Institute, Harvard Medical School in Boston (USA), the CONTACT-03 study…
Published in The New England Journal of Medicine (1) results of the phase 3 COSMIC-313 trial show that the addition…
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
